Working in partnership with the patient community to develop outline trial designs in CF

N. J. Rowbotham, S. Smith*, G. Davies, P. Leighton, O. Rayner, Z. Elliott, T. Daniels, A. R. Smyth

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)300-301
Number of pages2
JournalJournal of Cystic Fibrosis
Volume21
Issue number2
DOIs
Publication statusPublished - 22 Mar 2022
Externally publishedYes

Bibliographical note

Funding Information:
Members of the James Lind Alliance CF2 steering group include: Brownlee K, Collins S, Daniels T, Davies G, Duff AJA, Elliot ZC, Gathercole K, Hurley MN, Leighton PA, Rayner O, Rowbotham NJ, Smith S, Chandran S, Nash EF, Smyth AR (Chair), Wilson P. We would like to thank PwCF and their families, and the multi-disciplinary professional CF community for taking part in this survey. This work was funded by the UK CF Trust. G Davies was supported an NIHR Clinical Trials Fellowship at UCL. N Rowbotham was an NIHR Academic Clinical Fellow at University of Nottingham.

Funding Information:
GD reports personal fees from Chiesi Ltd and Vertex, outside the submitted work AS reports a research grant and personal fees from Vertex. These activities are outside the submitted work. In addition, Prof. Smyth has a patent alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof issued. TD reports personal fees from Vertex, Gilead & Chiesi. She has spoken at meetings supported by Teva, Zambon and Vertex. These activities are outside the submitted work.

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this